Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumours
A study to evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 alone and
in Combination with Nivolumab in Advanced (Solid Tumour) Cancers
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society